Answers are grounded in this paper and cite their sources.
The new diabetes drug troglitazone (Romozin) has been withdrawn from the market in Britain after an increasing number of reports of severe hepatic adverse events. The Food and Drug Administration in the United States, however, has decided that the benefits of treatment outweigh the risks, provided that patients receiving troglitazone are monitored frequently for …
No takes yet. Share an insight, caveat, or question.
J. Wise (1997) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: